Humacyte (HUMA) FCF Margin (2020 - 2026)
Humacyte's (HUMA) quarterly FCF Margin came in at 5467.98% in Q2 2026, up 339049.0% year-over-year from N/an in Q2 2025, and down 7.07% quarter-over-quarter from 5106.87% in Q1 2026.
Powered by 
Analysis
Humacyte (HUMA) FCF Margin (2020 - 2026) Analysis & Trends
Humacyte (HUMA) has reported FCF Margin for 4 consecutive years, with 5467.98% the latest figure, recorded in Q2 2026.
- On a quarterly basis, FCF Margin rose 339049.0% year-over-year to 5467.98% in Q2 2026; TTM through Jun 2026 was 4601.37%, a 839264.0% increase from a year earlier, with the FY2025 full-year figure at 5197.55%, changed N/A from the prior year.
- FCF Margin was 5467.98% for Q2 2026 at Humacyte, down from 5106.87% in the prior quarter.
- Over five years, FCF Margin peaked at 3181.01% in Q3 2025 and troughed at 8858.47% in Q2 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Krystal Biotech | 10.21 Bn | 9.36 Bn | 112.79 Mn | 59.74% |
| 2 | CRISPR Therapeutics AG | 5.02 Bn | 5.02 Bn | - | -826.50% |
| 3 | Iovance Biotherapeutics | 3.64 Bn | 3.34 Bn | 55.72 Mn | -66.71% |
| 4 | Legend Biotech | 3.53 Bn | 2.57 Bn | 251.50 Mn | -3.46% |
| 5 | uniQure | 2.98 Bn | 2.98 Bn | 5.49 Mn | -497.31% |
| 6 | Beam Therapeutics | 2.53 Bn | 2.53 Bn | - | -13,981.63% |
| 7 | Precigen | 2.39 Bn | 2.39 Bn | 52.17 Mn | -33.11% |
| 8 | Sarepta Therapeutics | 2.15 Bn | 1.35 Bn | 251.87 Mn | 48.98% |
| 9 | Vericel | 1.93 Bn | 1.76 Bn | 56.40 Mn | 18.67% |
| 10 | Humacyte | 133.72 Mn | 133.72 Mn | -825,000.00 | -5,467.98% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -5,467.98% |
| Mar 31, 2026 | -5,106.87% |
| Dec 31, 2025 | -5,602.36% |
| Sep 30, 2025 | -3,181.01% |
| Jun 30, 2025 | -8,858.47% |
| Mar 31, 2025 | -5,637.52% |
| Sep 30, 2021 | -12,697.93% |
| Sep 30, 2020 | -1.97% |